Coherus Moves Ahead With Pegfilgrastim On-Body Injector Rival
Dominant Neulasta Onpro Commands More Than 50% Of Pegfilgrastim Market
Coherus BioSciences is eyeing a potential late 2022/early 2023 timeline to introduce its proposed proprietary on-body injector device for its Udenyca pegfilgrastim biosimilar, after reporting positive results from a comparative clinical trial.
